Saiyu Tanaka

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

Medicine, Internal Medicine, Pharmacotherapy +12

Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients

Takashi Nakahara, Hideyuki Hyogo, Masato Yoneda et al. · Journal of Gastroenterology · 2013 · 163 citations

Medicine, Internal Medicine, Pathology +13

Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers

Takahisa Kawaguchi, Toshihide Shima, Masayuki Mizuno et al. · PLoS ONE · 2018 · 146 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study

Hiroshi Ishiba, Yoshio Sumida, Saiyu Tanaka et al. · Journal of Gastroenterology · 2018 · 129 citations

Veterinary Medicine, Internal Medicine, Pathology +10

Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study

Yasushi Honda, Takaomi Kessoku, Yoshio Sumida et al. · BMC Gastroenterology · 2017 · 117 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17